Zur Startseite von DrArbeit.de,
der deutschlandweiten Stellenbörse für Diplomarbeiten und Doktorarbeiten


Lupe2

Archiv - Stellenangebot

 

Dies ist ein Angebot aus der Datenbank von DrArbeit.de

Um die Datenbank komfortabel nach weiteren Angeboten durchsuchen zu können, klicken Sie einfach oben oder hier.

 
Archiv-Übersicht     Angebot Nr. 12934

Angebotsdatum: 10. Juli 2018
Art der Stelle: Doktorarbeit
Fachgebiet: Chemie > Radiochemie
Titel des Themas: Development of novel peptidomimetica for improved tumour targeting

Institut: Ludwig Boltzmann Institut Applied Diagnostics
Adresse:
Prof. Thomas Mindt
AKH Wien, Währiger Gürtel 18-20
1090 Wien
Tel.:    Fax.:
Bundesland:
Homepage: http://www.applied-diagnostics.at/
E-Mail Kontakt: mail

Beschreibung: The Ludwig Boltzmann Institute Applied Diagnostics in Vienna, Austria, follows a new dual biomarker concept for tumour diagnosis. The focus of the institute lies on the development of non-invasive diagnostic methods combining molecular epigenetic and genetic signatures and molecular imaging biomarkers for PET and SPECT analysis (http://www.applied-diagnostics.at/).

For a project funded by the Austrian Science Foundation we have an open position with immediate start date for a Ph.D. student (3.5 years) in the area of radiotracer development within the institute’s program line Imaging Biomarkers. The project involves the development of novel peptidomimetica for improved tumour targeting. [see e.g., 1] Candidates with a chemical or pharmaceutical background and the desire to get involved in application-driven and translational research are encouraged to apply. The candidates will work in a stimulating, interdisciplinary environment (radiopharmacy, nuclear medicine, chemistry, pharmacology and health economics) at the Medical University of Vienna and the University of Vienna.

Desired Skills and Experience
•MSc Degree in Chemistry or Pharmacy
•Knowledge in synthetic organic/inorganic/peptide chemistry or transition metal catalysis (e.g., CuAAC) and according analytical techniques (e.g. HPLC, NMR, MS)
•Experience in radiopharmaceutical sciences and/or in conducting biological assays (in vitro/in vivo) would be advantageous.
•Good communication skills in English and/or German.
•Motivation to work in a transdisciplinary team

The successful candidate will develop novel PET and SPECT tracers for tumour-targeting based on radiolabelled peptides/proteins and take part in the biological testing of the new compounds in vitro and in vivo.

Salary will be based according to the recommendations of the Austrian Science Foundation (FWF: https://www.fwf.ac.at/en/research-funding/personnel-costs/).

Application documents (cover letter, Curriculum Vitae, and contact data of 2-3 references) should be sent to Prof. Dr. Thomas Mindt: Thomas.Mindt@lbiad.lbg.ac.at.

[1] “1,2,3-Triazoles as Amide Bond Mimics: Triazole Scan Yields Protease-Resistant Peptidomimetics for Tumor Targeting” I. E. Valverde, A. Bauman, C. A. Kluba, S. Vomstein, M. Walter, T. L. Mindt Angewandte Chemie International Edition, 2013, 52, 8957-8960
Methoden:
Anfangsdatum: 1. September 2018
Geschätzte Dauer: 3,5
Bezahlung:
Papers:
Sonstiges:

Archiv-Übersicht